

**DEAL PROFILE**

**THE CARLYLE GROUP | PIRAMAL PHARMA SOLUTIONS**

**VALUES**

~\$2.8bn

~\$490mm

20%

Implied Enterprise Value

Equity Investment

Equity Stake

**THE CARLYLE GROUP**

**The Carlyle Group, Inc. (NasdaqGS:CG)**

The Carlyle Group is one of the world’s largest and most diversified global investment firms, with \$217bn of assets under management across four core business segments and 392 investment vehicles. Carlyle invests across a variety of core sectors, including healthcare. The firm was founded in 1987.

**TEV: \$14,858mm LTM EBITDA: \$357mm<sup>1</sup> LTM Revenue: \$1,545mm<sup>1</sup>**



**Piramal Enterprises Limited (BSE:500302)**

Piramal Pharma Solutions is the contract development and manufacturing arm of Piramal Enterprises Ltd., with operations across North America, Europe and Asia. The company is a global leader in integrated solutions and offer a unique platform of services across the drug lifecycle – from drug discovery and development to commercial manufacturing of drug substances and drug products.

**TEV: \$8,468mm LTM EBITDA: \$1,096mm<sup>2</sup> LTM Revenue: \$1,730mm<sup>2</sup>**

**BOURNE PARTNERS MARKET RESEARCH**

Bourne Partners provides strategic and financial advisory services to clients throughout the business evolution life cycle. In order to provide the highest level of service, we routinely analyze relevant industry trends and transactions. These materials are available to our clients and partners and provide detailed insight into the pharma, pharma services, OTC, consumer health, and biotechnology sectors.

**OVERVIEW**

On June 27, 2020, Piramal Enterprises Limited and The Carlyle Group announced that CA Clover Intermediate II Investments had agreed to invest fresh equity capital for a 20% stake in Piramal Pharma Limited. The transaction values the Pharma business at an EV of ~\$2.8bn, including an upside component of up to \$360mm depending on the company’s performance in 2021. This acquisition is one of the largest private equity deals in the Indian pharmaceutical sector and is expected to close in 2020, subject to customary closing conditions and regulatory approvals.

**HIGHLIGHTS**

The deal is an affirmation of the strength of Piramal Enterprises’ ability to build new, attractive and scalable businesses with a significant runway for continued organic growth and opportunities for consolidation. This new equity stake into Piramal Enterprises’ pharma business will be used as growth capital for the pharma businesses to expand capacity across Piramal Enterprises’ sites as well as to tap attractive acquisition opportunities globally, including in India. In addition, the infusion of funds will further strengthen Piramal Enterprises’ balance sheet and provide them with a war chest for the next phase of strategy. The transaction aligns with the Carlyle Asia Partners advisory team’s strategic thinking, regarding India as an attractive market. The advisory team stated that India is, “...a market where we continue to see many attractive investment opportunities where we believe we can collaborate with management teams to drive long-term value for companies and stakeholders.”

<sup>1</sup>LTM values as of 03/21/2020

<sup>2</sup>LTM values as of 03/31/2020

Source(s): S&P CapitalIQ, June 2020; The Carlyle Group